Following jousts between Vermont Sen. Bernie Sanders and Novo Nordisk, the Senate Committee on Health, Education, Labor, and Pensions will vote June 18 on whether to subpoena the drugmaker’s president about the cost of Ozempic and Wegovy.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
